NCT04658082 is a NA clinical trial of H.G.R (GWave) non-invasive glucometer in Type 2 Diabetes, sponsored by Prof. Amir Tirosh.

Who is sponsoring NCT04658082?

NCT04658082 is sponsored by Prof. Amir Tirosh.

What drugs are being tested in NCT04658082?

Interventions in NCT04658082: H.G.R (GWave) non-invasive glucometer.

What condition does NCT04658082 study?

NCT04658082 studies Type 2 Diabetes.

Is NCT04658082 still recruiting?

NCT04658082 is currently completed. Last updated 23 May 2022.

Last reviewed 2022-05-23 · How we verify

NCT04658082

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Trial of the Non-invasive H.G.R Glucometer

Completed NA Last updated 23 May 2022

What this trial tests

NA trial testing H.G.R (GWave) non-invasive glucometer in Type 2 Diabetes in 5 participants. Completed in 1 December 2020.

Timeline

7 October 2020

Primary endpoint
16 November 2020

1 December 2020

Quick facts

Lead sponsor	Prof. Amir Tirosh
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	5
Start date	7 October 2020
Primary completion	16 November 2020
Estimated completion	1 December 2020
Sites	1 location across Israel

Drugs / interventions tested

H.G.R (GWave) non-invasive glucometer

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Prof. Amir Tirosh

Who can join

18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A pilot study evaluating the accuracy of a non-invasive glucose monitor (GWave) with venous glucose measured by core laboratory during a glucose tolerance test (GTT) in patients with type 2 diabetes. The study is conducted on 5 subjects undergoing a 75gr GTT, with blood glucose measured at baseline and at 8 time points up to 180 minutes post glucose ingestion both by GWave non-invasive glucometer and by core lab glucose measurement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Pilot Trial to Evaluate the Accuracy of a Novel Non-Invasive Glucose Meter.
Schwarz Y, Konvalina N, Tirosh A. · · 2021 · cited 4× · PMID 34695917 · DOI 10.3390/s21206704

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04658082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Amir Tirosh
Last refreshed: 23 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04658082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing